Skip to main content
. 2024 Apr 16;20(8):1132–1139. doi: 10.1200/OP.23.00630

FIG 1.

FIG 1.

MMCDs comparing venetoclax with BTKi cohorts in second-line setting. *P < .05; ***P < .0001. BTKi, Bruton tyrosine kinase inhibitor; CLL, chronic lymphocytic leukemia; MMCD, mean monthly cost difference; PPPM, per patient per month; SE, standard error; USD, US dollars.